Pacira Pharmaceuticals (PCRX) PT Lowered to $39 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Truist Securities Double Downgrades Pacira Pharmaceuticals (PCRX) to Sell
August 13, 2024 6:06 AM EDTTruist Securities analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Sell with a price target of $8.00 (from $30.00).
The analyst comments "We revisit our core thesis on PCRX after our follow-up call with KOL conveys generic Exparel launch is... More
